Ovarian Cancer

Featured

Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance…
Videos
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
William Bradley, MD, discusses 5-year follow-up results from the SOLO-1 trial, which aimed to assess the long-term…
Quiz
Quiz: Is First-Line Niraparib Maintenance Cost-Effective for Patients With Advanced Ovarian Cancer?
True or False: In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is a…
Videos
Medicare Reimbursement Trends for Gynecologic and Urologic Procedures
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and…
Conference Coverage
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States
A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared…

News

Optimizing Germline Genetic Testing for Women With Breast or Ovarian Cancer
Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer

Guideline Updates

NCCN Releases Updated Treatment Guideline for Ovarian Cancer

Interviews

PARP Inhibitors in Front-Line and Maintenance Therapy of Ovarian Cancer: A Changing Standard of Care

Videos

Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost

Podcast

Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others

Conference Coverage

Olaparib Maintenance Demonstrates Long-Term PFS Benefit for Advanced Ovarian Cancer
Back to Top